{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:36:04Z","timestamp":1781037364876,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1546-0096-12-29","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T13:01:18Z","timestamp":1405515678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry"],"prefix":"10.1186","volume":"12","author":[{"name":"the Pediatric Rheumatology Collaborative Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E","family":"Sobel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermine I","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula W","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth S","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Chalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence K","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B","family":"Onel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Petiniot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shishov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Abramsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,16]]},"reference":[{"issue":"5","key":"1730_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00124743-200110000-00008","volume":"7","author":"HI Brunner","year":"2001","unstructured":"Brunner HI, Kim KN, Ballinger SH, Bowyer SL, Griffin TA, Higgins GC, Mier R, Passo MH, Rennebohm R, Schikler K, Lovell DJ: Current medication choices in juvenile rheumatoid arthritis II\u2013update of a survey performed in 1993. J Clin Rheumatol. 2001, 7 (5): 295-300.","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"1730_CR2","first-page":"2036","volume":"26","author":"RQ Cron","year":"1999","unstructured":"Cron RQ, Sharma S, Sherry DD: Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol. 1999, 26 (9): 2036-2038.","journal-title":"J Rheumatol"},{"issue":"1","key":"1730_CR3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3899\/jrheum.080073","volume":"36","author":"I Foeldvari","year":"2009","unstructured":"Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ: A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009, 36 (1): 174-182.","journal-title":"J Rheumatol"},{"issue":"3","key":"1730_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1521-6942(02)90234-2","volume":"16","author":"KJ Murray","year":"2002","unstructured":"Murray KJ, Lovell DJ: Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol. 2002, 16 (3): 361-378.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"1730_CR5","first-page":"985","volume":"33","author":"A Reiff","year":"2006","unstructured":"Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, Chen PY, Bolognese JA, Cavanaugh P, Reicin AS, Giannini EH: Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006, 33 (5): 985-995.","journal-title":"J Rheumatol"},{"issue":"2","key":"1730_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/art.20860","volume":"52","author":"N Ruperto","year":"2005","unstructured":"Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, Joos R, Zulian F, Schwarz R, Artamonova V, Emminger W, Bandeira M, Buoncompagni A, Foeldvari I, Falcini F, Baildam E, Kone-Paut I, Alessio M, Gerloni V, Lenhardt A, Martini A, Hanft G, Sigmund R, Simianer S: A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005, 52 (2): 563-572.","journal-title":"Arthritis Rheum"},{"key":"1730_CR7","unstructured":"Food and Drug Administration: Memorandum: Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk (Updated 2005). http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM106201.pdf ,"},{"issue":"2","key":"1730_CR8","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004, 31 (2): 390-392.","journal-title":"J Rheumatol"},{"issue":"4","key":"1730_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/01.rhu.0000173616.81928.44","volume":"11","author":"HI Brunner","year":"2005","unstructured":"Brunner HI, Johnson AL, Barron AC, Passo MH, Griffin TA, Graham TB, Lovell DJ: Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005, 11 (4): 194-204.","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"1730_CR10","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994, 37 (12): 1761-1769.","journal-title":"Arthritis Rheum"},{"key":"1730_CR11","unstructured":"Centers for Disease and Control Prevention: 2000 CDC Growth Charts for the United States: Methods and Development (Vital Health and Statistics, series 11, number 246). http:\/\/www.cdc.gov\/growthcharts\/2000growthchart-us.pdf ,"},{"key":"1730_CR12","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. http:\/\/www.fda.gov\/downloads\/regulatoryinformation\/guidances\/ucm126834.pdf ,"},{"key":"1730_CR13","first-page":"172","volume-title":"Statistics in Epidemiology: Methods, Techniques and Applications","author":"H Sahai","year":"1995","unstructured":"Sahai H, Khurshid A: Prospective (Cohort) Studies with Person-Time Data. Statistics in Epidemiology: Methods, Techniques and Applications. 1995, New York, NY: CRC Press LLC, 172-174."},{"issue":"4","key":"1730_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011, 63 (4): 465-482.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"1730_CR15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK: 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013, 65 (10): 1551-1563.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"S10","key":"1730_CR16","first-page":"493","volume":"64","author":"S Ringold","year":"2012","unstructured":"Ringold S, Hendrickson A, Wallace C, Sobel R: Adverse events in juvenile idiopathic arthritis: results from the enhanced drug safety surveillance (EDSS) pilot project [abstract]. Arthritis Rheum. 2012, 64 (S10): 493-","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1730_CR17","first-page":"367","volume":"17","author":"B Andersson G\u00e4re","year":"1999","unstructured":"Andersson G\u00e4re B: Juvenile arthritis - who gets it, where and when? a review of current data on incidence and prevalence. Clin Exp Rheumatol. 1999, 17 (3): 367-374.","journal-title":"Clin Exp Rheumatol"},{"issue":"3 Pt 2","key":"1730_CR18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1542\/peds.104.S3.623","volume":"104","author":"K Hoppu","year":"1999","unstructured":"Hoppu K: Patient recruitment\u2013European perspective. Pediatrics. 1999, 104 (3 Pt 2): 623-626.","journal-title":"Pediatrics"},{"issue":"5","key":"1730_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1542\/peds.2010-2585","volume":"127","author":"CL Tishler","year":"2011","unstructured":"Tishler CL, Reiss NS: Pediatric drug-trial recruitment: enticement without coercion. Pediatrics. 2011, 127 (5): 949-954.","journal-title":"Pediatrics"},{"issue":"3 Pt 2","key":"1730_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.104.S3.619","volume":"104","author":"PD Walson","year":"1999","unstructured":"Walson PD: Patient recruitment: US perspective. Pediatrics. 1999, 104 (3 Pt 2): 619-622.","journal-title":"Pediatrics"},{"key":"1730_CR21","first-page":"S100","volume":"62","author":"T Beukelman","year":"2010","unstructured":"Beukelman T, Xie F, Curtis J: Usage of TNFa inhibitors for the treatment of juvenile idiopathic arthritis: data from a national U.S. administrative claims database [abstract]. Arthritis Rheum. 2010, 62: S100-S101.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1730_CR22","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1007\/s00296-011-2084-7","volume":"32","author":"R Kochar","year":"2012","unstructured":"Kochar R, Walsh KM, Jain A, Spalding SJ, Hashkes PJ: Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. Rheumatol Int. 2012, 32 (10): 3055-3060.","journal-title":"Rheumatol Int"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1546-0096-12-29.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T03:09:49Z","timestamp":1649646589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/1546-0096-12-29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1186\/1546-0096-12-29","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,16]]},"assertion":[{"value":"14 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"29"}}